ArticleScientific reports2026
Protective effect of Baicalin against doxorubicin-induced cytotoxic and electrophysiological damage in human iPSC-cardiomyocytes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Doxorubicin (DOX) remains one of the most effective chemotherapeutic agents for a variety of solid tumors and hematological malignancies. Nevertheless, its clinical utility is restricted by DOX-induced cardiotoxicity (DIC), primarily driven by oxidative stress, inflammation, and apoptosis. Baicalin (BAI), a natural compound with antioxidant, anti-inflammatory, and anti-cancer properties, has shown cardioprotective effects in DOX-treated animal cardiac models, but its impact on human cardiomyocytes remains unexplored. This study was designed to assess the cardioprotective effects of BAI against human cardiac DIC using induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). hiPSC-CMs were pretreated with BAI and exposed to acute (1 µM for 24 h) and long-term (0.3 µM for 7d) DOX treatments, with or without different BAI concentrations (1 µM, 10 µM, and 25 µM). Multielectrode array (MEA) analysis, Tunel and cleaved-caspase 3 staining, reactive oxygen species (ROS) analysis, and sarcomere protein staining were performed to assess the effects of BAI on human DIC. BAI treatment alleviates DOX-induced cytotoxic injury, reducing apoptosis, oxidative stress, and preventing sarcomere disorganization. Moreover, BAI attenuated the long-term DOX-induced electrophysiological alterations, stabilizing field potential duration, beat rate, spike amplitude, and conduction velocity. These findings suggest the potential protective role of BAI against the DOX-induced human cardiac toxicity, supporting a potential clinical application in cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.